Sebelipase alfa
Top View
- GPI Class 30 – Endocrine and Metabolic Agents, Miscellaneous Review Time Frame: 11/2015 – 04/2017 Previous Class Review: 02/2016
- Covering Gene Therapy, Somatic Cell Therapy), and Recombinant Proteins Other Than Monoclonal Antibodies
- Pediatric Orphan Drug Indications: 2010–2018 Lauren Kimmel, BS,A Rena M
- Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
- 5.01.576 Drugs for Rare Diseases
- Partnerre Trigger Pharmaceuticals (At 5.21.21) Code Brand Name Generic Name Code Brand Name Generic Name J3590 Abecma®
- Sebelipase Alfa As Enzyme Replacement Therapy in Three
- 57 Orphan Drugs Approved by the EC Between 2012 and 2016 Were Found, of Which 40 (70.2%) Had Been Authorised in Spain
- Partnerre Trigger Pharmaceuticals (At 2.6.20)
- Reimbursement Criteria for Frequently Requested Drugs
- Rare Dyslipidaemias, from Phenotype to Genotype to Management: a European Atherosclerosis Society Task Force Consensus Statement
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- New Drugs Reviewed by CPG May 16, 2016
- Enzyme Related Therapies
- Corporate Medical Policy
- New Brunswick Drug Plans Formulary
- Environmental Assessment
- Lysosomes As a Therapeutic Target